DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Samidorphan is an investigational drug.
There have been 5 clinical trials for Samidorphan. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Schizophrenia, Alcohol Drinking, and Disease. The leading clinical trial sponsors are Alkermes, Inc. and [disabled in preview].
There are nineteen US patents protecting this investigational drug and one hundred and twenty-two international patents.
Recent Clinical Trials for Samidorphan
|A Phase 1 Safety Study in Adults With Schizophrenia||Alkermes, Inc.||Phase 1|
|A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers||Alkermes, Inc.||Phase 1|
|A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users||Alkermes, Inc.||Phase 1|
Top disease conditions for Samidorphan
Top clinical trial sponsors for Samidorphan
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Samidorphan||Start Trial||Compositions of buprenorphine and .mu. antagonists||Alkermes Pharma Ireland Limited (Dublin, IE)||Start Trial|
|Samidorphan||Start Trial||Opioid agonist antagonist combinations||Alkermes Pharma Ireland Limited (Dublin, IE)||Start Trial|
|Samidorphan||Start Trial||Methods for treating antipsychotic-induced weight gain||Alkermes Pharma Ireland Limited (Dublin, IE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|